779 related articles for article (PubMed ID: 33679703)
1. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():615240. PubMed ID: 33679703
[TBL] [Abstract][Full Text] [Related]
2. An overview of adjuvant formulations and delivery systems.
García A; De Sanctis JB
APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
[TBL] [Abstract][Full Text] [Related]
3. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
Front Immunol; 2018; 9():2874. PubMed ID: 30619259
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
5. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
6. Adjuvants for cancer vaccines.
Dubensky TW; Reed SG
Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
[TBL] [Abstract][Full Text] [Related]
7. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
8. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Immunogenicity and Protective Efficacy of a
Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
mSphere; 2019 May; 4(3):. PubMed ID: 31043512
[No Abstract] [Full Text] [Related]
10. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future.
Naghavi AO; Johnstone PA; Kim S
Curr Probl Cancer; 2016; 40(1):38-67. PubMed ID: 26656977
[TBL] [Abstract][Full Text] [Related]
13. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
Front Immunol; 2022; 13():936129. PubMed ID: 36059502
[TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvants revisited.
Aguilar JC; Rodríguez EG
Vaccine; 2007 May; 25(19):3752-62. PubMed ID: 17336431
[TBL] [Abstract][Full Text] [Related]
15. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines.
Castro-Díaz N; Salaun B; Perret R; Sierro S; Romero JF; Fernández JA; Rubio-Moraga A; Romero P
Vaccine; 2012 Jan; 30(2):388-97. PubMed ID: 22079266
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in adjuvants for vaccines against infectious diseases.
O'Hagan DT; MacKichan ML; Singh M
Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
[TBL] [Abstract][Full Text] [Related]
17. Designing and building the next generation of improved vaccine adjuvants.
Brito LA; O'Hagan DT
J Control Release; 2014 Sep; 190():563-79. PubMed ID: 24998942
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer.
Mora Román JJ; Del Campo M; Villar J; Paolini F; Curzio G; Venuti A; Jara L; Ferreira J; Murgas P; Lladser A; Manubens A; Becker MI
J Immunol Res; 2019; 2019():7076942. PubMed ID: 30847353
[TBL] [Abstract][Full Text] [Related]
19. Enhancing immune responses to tumor-associated antigens.
Higgins JP; Bernstein MB; Hodge JW
Cancer Biol Ther; 2009 Aug; 8(15):1440-9. PubMed ID: 19556848
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in vaccine delivery systems.
O'Hagan DT
Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]